Background

Mr. Roland Turck serves as the Head of Global Strategic Marketing Specialty Medicine at Bayer Healthcare AG. Mr. Turck has been Senior Advisor of The Board at Actinium Pharmaceuticals, Inc since February 04, 2015. Dr. Turck serves as Managing Partner at TurckBio. Prior to founding TurckBio, Dr. Turck led Bayer Healthcare's Global Specialty Medicine unit, where most relevant to Actinium, he played a leadership role in the commercialization of the alpha-radiopharmaceutical ... XofigoÂ® whose successful launch he prepared in close collaboration with Algeta ASA. Dr. Turck is a Medical Doctor with more than 20 years' pharmaceutical industry experience at Bayer, Berlex and Schering. He has extensive oncology experience having supported in various roles the development, global launch and commercialization of several leading oncology drugs including XofigoÂ®, StivargaÂ®, NexavarÂ® and Campath. Throughout his career, he gained broad experience in clinical development, regulatory, market access and commercialization of oncology drugs including radiopharmaceuticals such as XofigoÂ® which was the most commercially successful launch of a radiopharmaceutical product to date. At TurckBio, he has worked as an independent consultant for a number of leading private and public biotechnology and pharmaceutical companies. Mr. Turck has been a Director at Biotechnology Industry Organization since July 2011.

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.